Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report | BMC Cancer | Full Text

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report | BMC Cancer | Full Text

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report

Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of breast cancer susceptibility genes 1 and 2 (BRCA1/2) mutant ovarian and breast cancers, and are now being evaluated in metastatic c...

Authors:Andrew D. Simmons, Minh Nguyen and Elias Pintus

Citation:BMC Cancer 2020 20:215

Content type:Case report

Published on: 14 March 2020

• ViewFull Text
 
• ViewPDF